Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) FCF Margin (2020 - 2025)

Pliant Therapeutics (PLRX) has disclosed FCF Margin for 5 consecutive years, with 13079.41% as the latest value for Q4 2025.

  • Quarterly FCF Margin changed N/A to 13079.41% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5029.7% through Dec 2025, changed N/A year-over-year, with the annual reading at 7422.91% for FY2023, 642765.0% down from the prior year.
  • FCF Margin for Q4 2025 was 13079.41% at Pliant Therapeutics, up from 2586.63% in the prior quarter.
  • The five-year high for FCF Margin was 13079.41% in Q4 2025, with the low at 9987.5% in Q2 2023.
  • Average FCF Margin over 4 years is 380.62%, with a median of 1075.28% recorded in 2021.
  • The sharpest move saw FCF Margin surged 58154bps in 2022, then crashed -949341bps in 2023.
  • Over 4 years, FCF Margin stood at 1074.94% in 2021, then crashed by -56bps to 1677.66% in 2022, then plummeted by -495bps to 9987.5% in 2023, then soared by 231bps to 13079.41% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 13079.41%, 2586.63%, and 5032.76% for Q4 2025, Q3 2025, and Q2 2025 respectively.